Literature DB >> 17951326

The haemostatic role of tissue factor pathway inhibitor.

James T B Crawley1, David A Lane.   

Abstract

Under normal conditions the blood circulates freely within the confines of the vascular system, carrying oxygen, nutrients, and hormonal information around the body and removing metabolic waste. If blood gains access to extravascular sites, or the vasculature becomes pathologically challenged, hemostasis may be activated. This process is finely regulated by positive and negative feedback loops that modulate fibrin clot formation. Blood coagulation revolves around the activation and assembly of the components of the prothrombinase complex, which converts the inactive zymogen, prothrombin, into its active form, thrombin. This serine protease catalyzes the conversion of fibrinogen to fibrin, the structural scaffold that stabilizes platelet aggregates at sites of vascular injury. The extent of the hemostatic response is controlled by the action of inhibitory pathways, which ensure that thrombin activity and the spread of the hemostatic plug is limited to the site of vessel damage. This review article focuses on the major physiological regulator of tissue factor-induced coagulation, tissue factor pathway inhibitor, its expression, anticoagulant function, and its role in normal hemostasis.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17951326     DOI: 10.1161/ATVBAHA.107.141606

Source DB:  PubMed          Journal:  Arterioscler Thromb Vasc Biol        ISSN: 1079-5642            Impact factor:   8.311


  34 in total

Review 1.  Anti-inflammatory actions of serine protease inhibitors containing the Kunitz domain.

Authors:  Hiroshi Shigetomi; Akira Onogi; Hirotaka Kajiwara; Shozo Yoshida; Naoto Furukawa; Shoji Haruta; Yasuhito Tanase; Seiji Kanayama; Taketoshi Noguchi; Yoshihiko Yamada; Hidekazu Oi; Hiroshi Kobayashi
Journal:  Inflamm Res       Date:  2010-05-08       Impact factor: 4.575

2.  Tissue factor pathway inhibitor in activated prothrombin complex concentrates (aPCC) moderates the effectiveness of therapy in some severe hemophilia A patients with inhibitor.

Authors:  Kenichi Ogiwara; Keiji Nogami; Tomoko Matsumoto; Midori Shima
Journal:  Int J Hematol       Date:  2014-04-01       Impact factor: 2.490

3.  Endogenous tissue factor pathway inhibitor has a limited effect on host defence in murine pneumococcal pneumonia.

Authors:  Florry E van den Boogaard; Cornelis van 't Veer; Joris J T H Roelofs; Joost C M Meijers; Marcus J Schultz; George J Broze; Tom van der Poll
Journal:  Thromb Haemost       Date:  2015-04-02       Impact factor: 5.249

4.  Assembly of the prothrombinase complex on the surface of human foreskin fibroblasts: Implications for connective tissue growth factor.

Authors:  Mario C Rico; James J Rough; Joanne M Manns; Fabiola Del Carpio-Cano; Fayez F Safadi; Satya P Kunapuli; Raul A DeLa Cadena
Journal:  Thromb Res       Date:  2011-09-01       Impact factor: 3.944

5.  Air pollution upregulates endothelial cell procoagulant activity via ultrafine particle-induced oxidant signaling and tissue factor expression.

Authors:  S J Snow; W Cheng; A S Wolberg; M S Carraway
Journal:  Toxicol Sci       Date:  2014-04-20       Impact factor: 4.849

6.  Intact Toll-like receptor 9 signaling in neutrophils modulates normal thrombogenesis in mice.

Authors:  Osama M El-Sayed; Nicholas A Dewyer; Catherine E Luke; Megan Elfline; Adriana Laser; Cory Hogaboam; Steven L Kunkel; Peter K Henke
Journal:  J Vasc Surg       Date:  2015-10-23       Impact factor: 4.268

7.  C-terminal peptides of tissue factor pathway inhibitor are novel host defense molecules.

Authors:  Praveen Papareddy; Martina Kalle; Gopinath Kasetty; Matthias Mörgelin; Victoria Rydengård; Barbara Albiger; Katarina Lundqvist; Martin Malmsten; Artur Schmidtchen
Journal:  J Biol Chem       Date:  2010-06-30       Impact factor: 5.157

Review 8.  Inherited risk factors for venous thromboembolism.

Authors:  Ida Martinelli; Valerio De Stefano; Pier M Mannucci
Journal:  Nat Rev Cardiol       Date:  2014-01-14       Impact factor: 32.419

9.  Molecular basis of factor IXa recognition by heparin-activated antithrombin revealed by a 1.7-A structure of the ternary complex.

Authors:  Daniel J D Johnson; Jonathan Langdown; James A Huntington
Journal:  Proc Natl Acad Sci U S A       Date:  2009-12-22       Impact factor: 11.205

10.  Low plasma levels of tissue factor pathway inhibitor in patients with congenital factor V deficiency.

Authors:  Connie Duckers; Paolo Simioni; Luca Spiezia; Claudia Radu; Sabrina Gavasso; Jan Rosing; Elisabetta Castoldi
Journal:  Blood       Date:  2008-08-11       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.